MedTrace Logo

Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke

NCT05585606 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-02-24

No results posted yet for this study

Summary

A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study of the Safety and Neuroprotective Capacity of Scp776 in Subjects Undergoing Endovascular Thrombectomy for Acute Ischemic Stroke

Conditions

  • Acute Ischemic Stroke (AIS)

Interventions

DRUG

Placebo

Volume Matched Placebo

DRUG

scp776 (1.9 mg/kg)

Cohort 1 dose regimen: Intravenous (IV) slow injection(s) over 2 minutes \- 1.9 mg/kg

DRUG

scp776 (3.8 mg/kg)

Cohort 2 dose regimen: Intravenous (IV) slow injection(s) over 2 minutes \- 3.8 mg/kg

DRUG

scp776 (4.8 mg/kg)

Cohort 3 dose regimen: Intravenous (IV) slow injection(s) over 2 minutes - 4.8 mg/kg

DRUG

scp776 (all dose levels)

A composite group encompassing all participants who received any dose level of the investigational drug under evaluation.

Sponsors & Collaborators

  • Silver Creek Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-19
Primary Completion
2025-09-15
Completion
2025-09-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05585606 on ClinicalTrials.gov